Journal Virus Eradication 2019 5 125131 ConferenCe report Highlights Conference Retroviruses Opportunistic Infections 49 March 2019 Seattle WA USA Christina K psomas1 Sabine Kinloch2 1 european Hospital Marseille france 2 royal free Hospital nHS trust University College London UK Introduction 26th Conference retroviruses opportunistic Infections 2019 meeting CroI 2019 took place 49 March Seattle WA USA meeting provides uptodate information standing quality HIV prevention treatment cure research comorbidities case viraemia remission 18 months antiretroviral therapy Art discontinuation patient received stem cell transplantation known London patient highlights meeting produced excitement attendees international press ongoing new data issue potential terato genicity integrase inhibitors raised May 2018 cohort Botswana Impressive novel preventative therapeutic agents options HIV presented important issues terms clinical management opportunistic infections sexually transmitted infections comorbidities ageing cognitive dysfunction weight gain HIV1 cure reports control viraemia stem cell transplantation socalled London patient Dusseldorf patient 12 delayed viral rebound analytic treatment interruption AtI infusion CCr5 Zfntreated CD4 t cells 3 A report ex vivo vivo editing SIV genome nonhuman primates CrISprCas9 4 study multidose IV romidepsin increased HIV1 expression persons antiretroviral therapy Art ACtG A53155 presented cases control viraemia discontinuation antiretroviral therapy Art described included viraemia control 18 months London patient lymphoma treated chemotherapy stem cell transplant homozygous CCr5Δ32 donor 3 months patient similarly treated Dusseldorf leukaemia relatively lowlevel conditioning stem cell transplant 12 casereports confirm fact Berlin patient remained patient cured similar intervention isolated case terms viral remission intervention longer followup needed able conclude cure Although improves understand ing importance CCr5 receptor viral rebound great limitation process easily generalised openlabel pilot threearm study tebas colleagues presented zinc finger nuclease Zfn gene therapy ex vivo treatment CD4 t cells CCr5 Zfn rnAbased Corresponding author Christina K psomas Department Infectious Diseases Internal Medicine european Hospital Marseille france email kcpsomasgmailcom 2019 Authors Journal Virus Eradication published Mediscript Ltd open access article published terms Creative Commons License transfection rnA encoding Zfn SB 728 single dose cyclophosphamide 3 Individuals controlled terms HIV infection infusion modified cells resulted 25 disrupted CCr5 impact percent age cells cyclophosphamide potential delay viral rebound postArt interruption A new approach aimed integrated SIV LTR gag presented Burdo colleagues CrISprCas9 ex vivo vivo SIV genome editing nonhuman primates results showed SIV cleavage vitro pBMCs excellent biodistribu tion edited SIV genomes tissues 4 ACtG trial A5315 reported McMahon colleagues disappointing showed increase plasma viraemia multi doses romidepsin HDAC inhibitor given intravenously 5 changes singlecopy assay cellassociated DnA rnA measurements kick kill strategy HDAC inhibitors use romidepsin study raise safety concerns Broadly neutralising antibodies potential use cure research use reviewed Antiretroviral agents HIV1 development continuing drug development exciting new com pounds active multiresistant viruses longacting activity potential broadening impact immune novel nucleoside produced Merck MK8591 efdA inhibits reverse transcription translocation It potent active multiple resistant strains Its long halflife allow weekly dosing 6 It currently phase 2 clinical trial nCt03272347 treatment HIV1 infection oncedaily administra tion 025 075 225 mg combination doravirine class HIV1 capsid function inhibitor GS6207 devel oped Gilead potent antiviral activity multiclass resistant virus low predicted human clearance aqueous solubility It great fact parenteral administration given infrequently It reported meeting agent acts early late virus life cycle 7 phase I study evaluated safety tolerability pharmacokinetics Data healthy volunteers cohorts receiv ing different dosing 30 100 300 450 mg subcutane ously shows single dose 100 mg levels eC95 maintained 12 weeks sideeffects reported Based interim data welltolerated single dose administered subcutaneously healthy subjects supported dosing interval 3 months 8 DeJesus colleagues presented results 10day phase 2a dosefinding study GSK maturation inhibitor GSK2838232 33 participants Binding gag targets 125 ConferenCe report Journal Virus Eradication 2019 5 125131 latestage viral lifecycle new compound follows discontinuation previous maturation inhibitors good potency broad activity It shown good tolerability twopart study presented 150mg cobicistat boosting Doses tested 20 50 100 200 mg daily participants mean CD4 cell counts 540 cellsmm3 58000 HIV1 copiesmL Mean viral load decrease 15 log10 200mg dose 10 days 12 log10 50 100mg doses available resistance data genotypic changes A364AW gag 9 need development new compound activity nrtI resistance nrtI candidate GS9131 potent activity HIV1 virus nrtI resistance broad activity HIV1 subtypes It monoaminate prodrug nucleotide analogue GS9148 acts chain termination low potential mitochondrial renal toxicity activity major nrtI resistance 10 A longacting LA combination important development HIV1 treatment At meeting studies fLAIr AtLAS presented LA combination cabotegravir CAB nonnucleoside reverse transcriptase inhibitor nnrtI rilpivirine rpV shown maintain virological sup pression 1112 fLAIr study phase 3 openlabel randomised controlled trial Artnaïve adult participants aimed establish virological suppression participants integrase inhibitor singletablet regimen abacavirdolutegravirlamivudine ABC DtG3tC continued participants switched LA CABrpV intramuscular administration 4 weeks safety primary endpoint 48 weeks aimed showing noninferiority compared oral comparator 566 naïve individuals Art started ABCDtG3tC partici pants undetectable 20 weeks randomised continue regimen switch shortacting CABrpV followed LA CABrpV 11 AtLAS study evaluated efficacy safety tolerability switching LA CABrpV current antiretroviral regimen virologically suppressed adults HIV1 616 viro logically suppressed individuals pI nnrtI integrase inhibi tors regimens participants remained regimen switched oral CABrpV 4 weeks followed LA CAB rpV 48 weeks In studies combination shown welltolerated discontinuations noninferiority demonstrated 1112 A new generation potent broadly neutralising antibodies bnAbs developed bnAbs great pre ventative therapeutic cure agents antiviral potency coupled potential activate immune responses importance cure strategies However development resistance single agents treatment leading combination agents testing addition immunomodulators oral tolllike receptor 7 tLr7 agonist GS9620 pGt121 IgG1 monoclonal antibody Ab targeting V3 envelope potent neutralising capacity 6070 HIV1 strains It tested preventative thera peutic studies nonhuman primates showing association GS9620 control viraemia Art initiation At conference human phase I study presented Kathryn Stephenson pGt121 tested individuals HIV1 Art individuals HIV1 study dose escalating phase pGt121 administered single 126 CK psomas S Kinloch infusion 3 10 30 mgkg subcutaneously 3 mgkg followed openlabel phase pGt121 given 30mgkg infusion viraemic adults Art high low HIV1 viral load small cohort patients A participants low viral load arm showed longterm viral suppression It safe good tolerability good pharmacokinetic pK profile Its impact host immunity investigation 13 novel compound GS9722 described inclass effectorenhanced bnab HIV cure It targeted eliminating latently infected cells Compared pGt121 shown neutralisation breadth potency improved druglike properties risk immunogenicity enhanced effector function optimised pK function It planned use combination bnAbs 14 presentation pegu colleagues trispecific broadly neutralising antibody compound potent antiviral activity exciting development Combination antibodies aimed preventing development resistance HIV1 antibod ies interact CD4 binding site membrane proximal external region Mper V1V2 glycan lead enhanced neutralisation intact IgG1 backbone potent fc effector functions animal studies promising mediating ADCC phagocytosis 1516 trispecific HIV broadly neutralis ing antibodies demonstrate potent neutralisation antibody dependent cellular cytotoxicity ADCC vitro mediate antiviral activity vivo Second thirdline antiretroviral therapy With widespread use integrase inhibitors presence resistance studies presented clarify efficacy secondgeneration integrase inhibitors situation DAWnInG study noninferiority randomised phase 3b openlabel study conducted evaluate safety efficacy DtG nrtIs compared lopinavirritonavir LpVr nrtIs participants firstline Art nnrtI plus nrtIs failing Dolutegravir shown previ ously superior LpVr comparison DtGbased regimen versus WHorecommended secondline regimen 17 presentation showed advantage DtG based regimen LpVrbased regimens included fully active nrtI persisted regardless baseline nrtI resistance post hoc analysis M184V mutation present majority patients isolation 25 present individual DtG outperformed LpVr K65r mutation present 30 participants 24 thymidineanalogue mutation tDf zidovudine included baseline regimens participants mutations high responses observed DtG arm participant numbers small 18 ongoing phase 3 randomised doubleblinded GS 4030 study enrolled 565 participants looking wellcontrolled patients documented baseline resistance drug classes integrase inhibiters randomisation involved staying DtG tenofovir tAfftC regimen switch 11 bictegravir BICftCtAf 48 weeks In total 82 462565 participants preswitch genotypic data available planned interim analysis 12 weeks followup showed high rate baseline nrtI resistance 24 99 participants HIV1 viral load 50 copiesmL primary nnrtI protease inhibitor pI resistance mutations present 24 8 Journal Virus Eradication 2019 5 125131 ConferenCe report participants respectively preexisting integrase inhibitor muta tions 5 participants 19 Andreatta colleagues Gilead presented resistance virological data longterm BICftCtAf efficacy studies 1844 1878 2 yearopenlabel BICftCtAf patients archived resistance 20 preexisting primary nrtI 16 nnrtI 21 low level integrase level resistance 19 detected development resistance noted time analysis maintenance virological control Santoro colleagues looked aspect preexisting resistance secondgeneration integrase inhibitors bictegravir study aimed defining genotypic phe notypic resistance profiles BIC integrase inhibitors highly treatmentexperienced multiresistant patients Italian preStIGIo registry treatment twicedaily raltegravir rAL DtGbased regimens failed 21 Gen eSeqIn phenoSenseIn assays performed twentytwo samples 17 patients evaluated median time diagnosis duration treatment 20 years Median viral load CD4 t cell count 45 log10 copiesmL 168 cellsmm3 respectively primary integrase resistance substitu tions e138AK Y143CHr Q148H n155H present 1422 samples G140S Q148H muta tions 1122 samples All 14 samples showed resistance elvitegravir raltegravir BIC DtG samples showing L74M e138K G140S Q148H L74M t97A S119t e138K G140S Y143r Q148H sub stitutions Intermediate resistance reported 814 isolates BIC 914 isolates DtG Median foldchange range values BIC 31 0666 DtG 61 08186 elvitegra vir 164 26164 raltegravir 188 27197 14 samples Data team Italian investigators Saladini colleagues described vitro activity DtGBICelvitegra virCAB firstgeneration integrase inhibitorresistant HIV1 plasma samples 19 patients major InStI mutations 22 integrase inhibitors DtG BIC CAB showed comparable activity Q148H addition mutations integrase inhibitors associated decreased susceptibility drugs tested Data indicates Q148H mutation pathway raltegravir failing appeared detrimental use second generation InStIs elvitegravir failing Pregnancy Since report significant increase neural tube defects cases Botswana tsepamo cohort women exposed drug conception later pregnancy reports use integrase inhibitors pregnancy review cohorts data tsepamo cohort awaited available 2019 report 1400 pregnancies Several databases clearly highlighted relationship use integrase inhibitors neural tube defects studies compared use efavirenz integrase inhibitors pregnancy raltegravir DtGbased Art regimens shown virologically superior efavirenz based regimen pregnant women 2327 Contraception Issues drugdrug interaction remain paramount case contraception previous reports highlighted efavirenz decreases levonorgestrel concentration subdermal implants unintended pregnancy consequence It disappoint ing learn doubling levonorgestrel dose 150 mg 300 mg overcome interaction 2831 Double dose levonorgestrel implants fully overcome interaction efavirenz clear doubledose able prevent pregnancies STIs impression déjà vu Jeanne Marrazzo University Alabama Birmingham USA presented resurgent sexually transmitted infections StIs HIV care prevention 32 Dr Marrazzo started talking dramatic explosion StIs wwwcdcgovstd 3334 Indeed burden infections concern char acteristics antimicrobial resistance treatment gon orrhoea 24 countries reported decreased susceptibility ceftriaxone 81 azithromycin 35 incidence syphilis preAIDS era estimates 153 increase com pared 2013 36 collision methamphetamines networks reemergence hepatitis C reappearance classics LGV rectitis tD 05 But role StIs Getting Zero StI burden scaling prep independent HIV incidence 3738 drivers HIV spread including economic gender inequality considered 3942 In context useful deploy rapid accurate diagnostic tests particularly high HIV incidence settings establish StI screen ing asymptomatic people recognise pattern StIs context HIV Comorbidities Artassociated comorbidities weight gain occupied particular place CroI tD08 themed Discussion Session inaugurated Jordan e Lake University texas Houston Houston tX US presented weight gain assessment follow ing switch InStIbased Art 972 AIDS Clinical trials Group ACtG participants ACtG protocols A5001 A5322 68 pI 31 nnrtI 2 nonInStI median 78 years parent trial entry 43 Median age switch 50 years CD4 t cell count 511 cellsmm3 BMI 264 kgm2 539 switched rAL 222 eVG 211 DtG In adjusted models white black ethnicity age 60 BMI 30 kgm2 associated greater weight gain following switch women age 60 greatest risk factor men Kassem Bourgi Vanderbilt University nashville tn USA pre sented results weight changes initiating Art treatmentnaïve people living HIV north American AIDS Cohort Collaboration research Design nAACCorD44 Among 4112 individuals initiating InStIbased regimens 2007 2016 2106 rAL 1510 eVG 477 DtG weight gain greatest individuals starting InStI At 2 5 years individuals InStI gained 44 58 respectively compared 33 41 taking nnrtIs P0001 43 50 pIs P068 mechanisms differences poorly understood Grace A McComsey Case Western reserve University Cleveland oH USA described demographic clinical treatment characteristics treatmentexperienced adults virally sup pressed HIV 3 annual weight gain recent years 20132018 observational retrospective study US clinical practice 45 In total 3468 patients followedup median time 19 months Among 1045 Highlights CroI 2019 127 ConferenCe report Journal Virus Eradication 2019 5 125131 participants 3 annualised weight gain compared 2423 patients higher proportions weight normal BMI baseline female age 50 psy chiatric disorders lower rates comorbidities CKD CVD DM hyperlipidaemia hypogonadism In multivariable logistic regression analysis authors InStI use independently associated weight gain suggesting population weight changes primarily driven factors Anne Marie Kerchberger emory University Atlanta GA USA highlighted results Womens Interagency HIV Study WIHS evaluated change body weight body measurements blood pressure virologically suppressed women living HIV WLHIV46 Women switched added InStI Art SWAD group compared women remained non InStI Art StAY group In total 1118 WIHS participants 884 StAY 234 SWAD followed average 20 01 years Mean baseline age 488 88 years In population InStIs associated significant increases body weight body mass index body circumference measurements blood pressure short period time significant dif ferences outcomes observed InStI type raphael J Landovitz University California Los Angeles CA USA presented results cabotegravir studies weight gain regimen containing molecule 47 Hptn 077 phase 2a randomised placebocontrolled study dosedoseinterval regimens cabotegravir enrolled 199 HIV uninfected participants sites US 4 Brazil 1 subSaharan Africa 3 Median weight change 41 weeks 11 IQr 0930 CAB arm 10 IQr 1232 placebo arm P066 In longitudinal statistical analyses statistically significant differences change weight weeks 0 41 CAB versus placebo treated participants aggregate sex dosing cohort age raceethnicity smoking status BMI baseline BMI category Changes fasting glucose fasting lipids weeks 0 41 different CAB placebo analysis suggests CAB different effects weightweight gain dolutegravir Sara H Bares University nebraska Medical Center omaha ne USA explored changes immune activation following Art initiation large randomised ACtG trials A5202 A525748 In total 340 participants selected median preArt age 42 years CD4 cell count 273 cellsmm3 HIV1 rnA 47 log10 copiesmL 49 women 33 white 42 black 24 Hispanic While preArt BMI similar gainers maintainers overall sex gainers significantly lower preArt CD4 cell counts versus maintainers In adjusted models normal preArt BMI preArt IL6 stnfrII Ip10 sCD163 higher gainers versus maintainers Association weight gain week 96 changes biomarkers differed sex women gained weight smaller declines biomarkers compared men gained In total higher pretreatment immune activation markers significantly associated weight gain following Art initia tion controlling preArt CD4 counts Weight gain attenuates decline immune activation markers fol lowing Art initiation women women increased risk complications weight gain Cardiac morbidity heart communications noncommunicable Diseases treated HIV Kristina Crothers University Washington Seattle WA USA assessed 25509 people living HIV CfAr network Integrated Clinical 128 CK psomas S Kinloch Systems CnICS cohort CopD myocardial infarction MI risk 49 CopD associated significantly increased risk MI adjusted hazard ratio aHr 209 95CI 150291 adding smoking aHr 188 95CI 134263 Matthew freiberg Vanderbilt University nashville tn USA analysed data 144362 veterans 30 living HIV Veterans Aging Cohort Study prospective study veterans living HIV age sex raceethnicity clinical site matched veterans HIV terms risk sudden cardiac death SCD50 In analysis adjustment confounders veterans living HIV 14 higher risk SCD hazard ratio114 95 CI 104125 compared veterans HIV risk highest sustained high HIV viral loads low CD4 cell counts Linda Ann Battalora Colorado School Mines Golden Co USA calculated mortality rates 17 years longitudinal prospective observational cohort HopS HIV outpatients Study currently conducted US cities evaluating association bone fractures mortality 51 Among 6826 HopS participants followed median 62 years 502 7 incident fracture recorded 729 10 died Median age fracture 48 years interquartile range 4155 years patients 165 major osteoporotic fractures died crude mortality 15 100 personyears py 146 frac tures sites died crude mortality 13 100 py In multivariable analysis incident fracture significantly associated allcause mortality Hazard ratio 15 95 CI 1219 multiple factors notably nadir CD4 cell count 200 cellsmm3 nonAIDS cancer hepatitis C infection chronic liver renal cardiovascular disease comorbidity Prevention Sharon L Hillier MageeWomens Hospital UpMC pittsburgh pA USA gave interesting update HIV prevention Committee Workshop new Investigators trainees 52 She said new HIV infections declined 5176 start pepfAr success HIV epidemic control disproportionate age group belonging minority group rates HIV Africa times higher US 10 times higher europe terrible mismatch people real need prep people finally In terms prep phase3 DISCoVer study 53 randomised 11 doubleblind activecontrolled study conducted north America Canada europe cismen sex men MSM transgender women tGW high risk HIV acquisition objec tive efficacy safety ftCtAf versus ftCtDf prep A total 5387 adults treated 94 sites 11 countries mean age 34 years range 1876 years 9 black 2 tGW 25 prior prep use 41 receptive condomless anal sex partners 90 days study entry HIV incidence rate ftCtAf ftCtDf low significantly background rate risk prep US In 2 years follow ftCtAf ftCtDf given daily tolerated low discontinuation rates primary endpoint analysis reported HIV incidence 22 HIV infections arms diagnosed 8756 py followup incidence rate ratio 047 95 CI 019115 establishing noninferiority ftCtAf ftCtDf HIV prevention effectiveness prep real life better clinical trials 54 failures reported context increased andor improper use 5556 Screening Journal Virus Eradication 2019 5 125131 ConferenCe report difficulties instance expose nonreactivity fourth generation assay reach 18 acute infection studies 57 prep failures causes ambiguous HIV screening test results System failures refer lack limited access prep unavailability lack awareness people risk healthcare providers cost Doctors failures refer insufficient knowledge prep failure rule HIV infection starting renewing prep reluctance prescribe prep people failures deferred improper use prep Assay failures refer challenges HIV diagnosis low sensitivity HIV tests daysweeks following HIV acquisition prep failures lead drug resistance prep started maintained person acquired HIV In clinical trials cases HIV infec tion resistance occurred prep started undiagnosed HIV infection overall true biomedical failures prep remain rare expected results Hptn 071 popArt trial presented 58 primary result trial presented professor richard Hayes London School Hygiene tropical Medicine Hptn 071 popArt trial designed deliver ing doortodoor combination package including HIV testing linkage treatment prevention achieve high coverage Art people living HIV number new HIV infections reduced compared current stand ard care approaches study design follows million people living 21 urban communities South Africa Zambia agreed community participate study 21 communities randomly allocated approaches matched triplets baseline levels HIV prevalence Seven communities allocated arm A trial offered communitywide HIV combination pre vention approach seven arm B communities offered householdbased HIV testing education communities antiretroviral treatment Art offered line current national guidelines seven arm C communities received current standardofcare approach HIV testing prevention treatment Art available routine government HIV clinics 21 communities irrespective study arm popArt intervention included HIV care Art prevention offered resident 21 commu nities involved trial government partners local healthcare facilities continued standardofcare arm C communities changes national guidelines policy Art initiation changed lifetime trial implemented accordance local recommendations Art initiation guidelines changed study period offer universal Art irrespective CD4 cell counts 2016 In addition routine government healthcare facility provision HIV testing prevention treatment popArt intervention employed new cadre staff community HIV care providers referred CHips CHips lay counsellors specially trained work household community annual basis offering HIV counselling testing prevention treatment provision condoms tB screening testing sexual reproductive health tests In cases requiring medical care treatment CHipS teams encouraged supported HIVpositive clients attend remain care government healthcare clinics In terms primary outcome number new HIV infections community measured study period 20142018 separately recruited randomly selected cohort approximately 20000 individuals com munity consented blood test taken annually HIV testing main outcome trial compare HIV incidence study arm time trial 2014 2018 arms A versus C arms B versus C based blood collected research cohort results intervention overall reached UnAIDS 909090 targets viral suppression people living HIV increased intervention arms baseline approximately 55 70 end trial period resulted 30 decline new HIV infections communities HIV prevention including homebased HIV counselling testing provided referral HIV care treatment people testing positive HIV according country guidelines arm B finding highly statistically significant lower reduction HIV incidence 7 comparing arm A communities arm C statistically significant lack impact arm A communities difficult explain present ongoing analyses exploring A post hoc analysis combining impact arms A B versus C demonstrated overall statistically significant reduction HIV incidence 20 overall trial showed communitywide services enhance coverage knowledge HIV status Art coverage level leads significant reductions HIV incidence Hepatitis C Jürgen K rockstroh University Bonn Germany described dynamics acute HCV Western europe 59 With advent highly successful tolerated direct acting antiviral DAA combinations HCV elimination appears reachable goal Global Health Sector Strategy GHSS calls elimination viral hepatitis public health threat 2030 reducing new infections 90 mortality 65 major obstacles overcome order approach HCV elimina tion underdiagnosis 20 people HCV worldwide having diagnosed far insufficient treat ment uptake 71 million people thought infected HCV 2015 176 million people received HCV treatment 2016 Additionally national studies netherlands Switzerland significant 50 reduction incidence newly acquired acute HCV infections increasing treatment uptake MSM HIV HCV infection current HCV outbreaks risk HCV reinfections clearly weakens success earlier HCV treatment initiation earlier acute HCV diagnosis needed order impact HCV dynamics Lucy Garvey Imperial College Healthcare nHS trust London UK described HCV incidence kinetics MSM living HIV London following wider access DAA therapy 60 While BHIVA aims cure HCV coinfections 100 2021 modelling work predicts significant scaleup HCV treatment important 61 Using real world experience Sanjay Bhaganis group examined trends incidence acute HCV 2013 2018 central London HIV clinics MSM living HIV constitute potential target microelimination In total 256 acute HCV diagnoses identified 45 reinfections median age 43 years 85 virologically suppressed Incidence HCV episode peaked 151000 95CI 1019 personyears follow upin 2015 rates declined 79 2018 change screening Highlights CroI 2019 129 ConferenCe report Journal Virus Eradication 2019 5 125131 practices reinfection rates increased 9 47 study period patients diagnosed acute HCV study period likely awaited chronic infection receive DAAs nHS average 23 months following diagnoses majority individuals received treatment clinical trial recent years average 10 months time diagnosis starting HCV treatment reduced average 409 months 2013 31 months 2018 Adeel A Butt pittsburgh Healthcare System pA USA presented results impact newer DAA regimens subse quent incidence risk diabetes comparatively untreated pegylated interferonribavirin peGrBVtreated controls electronically retrieved Cohort HCV Infected Vet erans erCHIVeS62 researchers identified 4764 peGrBV treated 21279 DAAtreated number untreated controls Diabetes incidence rate 95 CI1000 personyears follow 198 183214 peGrBV 989 87111 DAAtreated persons P0001 Among treated rates 133 122145 sustained virological response SVr 192 174211 SVr P00001 treatment associated larger reduc tion incident diabetes rate persons advanced fibrosiscirrhosis absolute difference 29 fIB4 125 57 fIB4 126325 98 fIB4 325 DAA treatment Hr 048 95CI 042056 SVr Hr 081 95CI 070093 associated significantly reduced risk diabetes useful mitigating extrahepatic complications HCV In context growing incidence hepatocellular carcinoma HCC people living HIV 1996 Jessie torgensen University pennsylvania philadelphia pA USA conducted cohort study VACS order determine impact HIV CD4 cell count HCC risk 63 identified 278 incident cases HCC median age 56 years striking 43 95 CI 3749 patients time HCC diagnoses markers advanced hepatic fibrosiscirrhosis fIB4 fIB4 325 contrast general population 13 HCC occur cirrhosis Among patients higher proportion morbid obesity BMI30 kgm2 diabetes chronic hepatitis B independently associated incident HCC In multivari able models patients baseline fIB4 325 chronic hepatitis B C increased risk HCC development In contrast patients low baseline markers hepatic fibrosiscirrhosis fIB4 325 HIV CD4 cell count significant chronic hepatitis B C Specifically 24 increased risk HCC log increase HIV viraemia 57 increased risk HCC people 11 months detectable viraemia Catherine Anne Chappell MageeWomens Hospital UpMC pittsburgh pA USA presented pilot study safety virological response ledipasvir 90 mgsofosbuvir 200 mg LDVSof therapy pregnancy 64 context ongoing hepatitis C virus epidemic young people US including pregnant women 200 women year6566 Seven women enrolled white median age 32 range 2538 years median HCV viral load enrolment 518173 range 1034573757923 copiesmL All rapid response therapy achieved SVr12 All adverse events related LDVSof grade 2 All seven participants delivered term undetectable HCV viral loads delivery oneyear followup infants ongoing results suggest viral response similar nonpregnant individuals 130 CK psomas S Kinloch References All abstracts presented Conference Retroviruses Opportunistic Infections March 2019 held Seattle WA USA marked 1 Gupta rK Abduljawad S McCoy L et al Sustained HIV1 remission following 2 homozygous CCr5 delta32 allogenic HSCt Abstract 29LB Jensen Beo Knops e Lubke n et al Analytic treatment interruption AtI allogeneic CCr5D32 HSCt AML 2013 Abstract 394 3 tebas p Jadlowsky J Shaw p et al Delayed viral rebound AtI infusion CCr5 Zfntreated CD4 t cells Abstract 25 4 Burdo tH Manucuso p Kaminski r et al Ex vivo vivo editing SIV genome nonhuman primates CrISprCAS9 Abstract 24 5 McMahon D Zheng L Cyktor JC et al Multidose IV romidepsin increased HIV1 expression persons Art ACtG A5315 Abstract 26 6 Grobler J fillgrove K Hazuda D et al MK8591 potency pK provide high inhibitory quotients low doses QD QW Abstract 48 7 Yant Sr Mulato A Stepan G et al GS6207 potent selective firstinclass 8 longacting HIV1 capsid inhibitor Abstract 4 Sager Je Begley r rhee M et al Safety pK subcutaneous GS6207 novel HIV1 capsid inhibitor Abstract 141 9 DeJesus e Harward S Jew rC et al A phase IIa study novel maturation inhibitor GSK2838232 HIV patients Abstract 142 10 Ibanescu rI oliviera M Spira B et al favorable outcome vitro selections novel nrtI prodrug GS9131 Abstract 482 11 orkin C Arasten K HernandezMora G et al Longacting cabotegravir rilpivirine HIV maintenance fLAIr week 48 results Abstract 140LB 12 Swindells S AndradeVillanueva Jf richmond GJ et al Longacting cabotegravir rilpivirine maintenance therapy AtLAS week 48 results Abstract 139 13 Stephenson Ke Julg B Ansel J et al therapeutic activity pGt121 monoclonal antibody HIVinfected adults Abstract 145 14 thomsen nD Balakrishnana M pace CS et al GS9722 firstinclass effector enhanced broadly neutralizing antibody HIV cure Abstract 356 15 Xu L pegu A rao e et al trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection macaques Science 2017 358 8590 16 pegu A Xu L Demouth M et al potent antiviral activity trispecific broadly neutralising antibodies Abstract 28 17 Aboud M Kaplan r Lombaard J et al Superior efficacy dolutegravir DtG plus 2 nucleoside reverse transcriptase inhibitors nrtIs compared lopinavirritonavir LpVrtV plus 2 nrtIs secondline treatment interim data DAWnInG study IAS 2017 July 2017 paris france Abstract tUAB0105LB 18 Brown D Wang r Underwood M et al DtG vs LpVr DAWnInG efficacy baseline nrtI resistance secondline nrtI use Abstract 144 19 Acosta rK Willkom M Andreatta K et al High level preexisting nrtI resistance prior switching BftAf Study 4030 Abstract 551 20 Andreatta K WM Martin r Longterm BftAf switch efficacy patients archived preexisting resistance Abstract 552 21 Santoro MM fornabaio C Malena M et al Susceptibility bictegravir highly ArVexperienced patients InStI failure Abstract 550 22 Saladini f Giannini A Boccuto A et al In vitro activity DtGBICeCAB firstgeneration InStIresistant HIV1 Abstract 549 23 Hill A van Ven nS pozniak A et al reports neural tube defects 8 ArtS fDA WHo eMA UK safety databases Abstract 746 24 Kintu K Malaba t nakibuka J et al rCt dolutegravir vs efavirenzbased therapy initiated late pregnancy DoLpHIn2 Abstract 40LB 25 Mirochnick M Shapiro De Morrison L et al randomized trial raltegravirArt vs efavirenzArt initiated pregnancy Abstract 39LB 26 Shamsuddin HH raudenbush CL Sciba BL et al evaluation neuraltube defects exposure raltegravir pregnancy Abstract 745 27 Sibiude J Le Chenader J Mandelbrot L et al increase birth defects infants exposed integrase inhibitors conception Abstract 744 28 neary M Lamorde M olagunju A et al effect gene variants levonorgestrel pharmacokinetics combined antiretroviral therapy containing efavirenz nevirapine Clin Pharmacol Ther 2017 102 529536 29 patel rC Morroni C Scarsi KK et al Concomitant contraceptive implant efa virenz use women living HIV perspectives current evidence policy implications family planning HIV treatment guidelines J Int AIDS Soc 2017 20 21396 30 roberts o rajoli rKr Back DJ et al physiologically based pharmacokinetic model ling prediction effects dose adjustment drugdrug interactions levonorgestrel contraceptive implants efavirenzbased Art J Antimicrob Chem 2018 73 10041012 31 Scarsi KK Darin KM nakalema S et al Unintended pregnancies observed combined use levonorgestrel contraceptive implant efavirenzbased antiretroviral therapy threearm pharmacokinetic evaluation 48 weeks Clin Infect Dis 2016 62 675682 32 Marrazzo JM Denial doom destiny resurgent StIs HIV care prevention Abstract 12 33 Braun DL Marzel A Steffens D et al High rates subsequent asymptomatic sexu ally transmitted infections risky sexual behavior patients initially presenting primary human immunodeficiency virus1 infection Clin Infect Dis 2018 66 735742 34 pathela p Jamison K Kornblum J et al Lymphogranuloma venereum increas ingly common anorectal infection men sex men attending new York City sexual health clinics Sex Transm Dis 2019 46 e14e17 35 Stenger Mr pathela p Anschuetz G et al Increases rate Neisseria gonor rhoeae gay bisexual men sex menfindings Sexually transmitted Disease Surveillance network 20102015 Sex Transm Dis 2017 44 393397 36 Dionneodom J Westfall A Mugavero MJ et al Incident syphilis rates predic tors US women HIV 20052016 Abstract 47 Journal Virus Eradication 2019 5 125131 ConferenCe report 37 Unemo M Bradshaw CS Hocking JS et al Sexually transmitted infections chal 53 Hare CB Coll J ruane p et al phase 3 DISCoVer study daily ftAf f lenges ahead Lancet Infect Dis 2017 17 e235e279 38 Mayer KH Maloney K Levine K et al Why StIs increasing atrisk boston men screening plus Abstract 851 39 Davey DJ nyemba D Greater weight gain treatmentnaive persons starting integrase inhibitors Abstract 1003 40 Jasumback CL perry S Matsenjwa M et al prevalence chlamydia gonorrhea HIVpositive adolescents eSwatini Abstract 1002 41 ramchandani M Litvack J Maxwell C et al Hearing loss unselected individuals syphilis Abstract 1013 42 robertson K Mendoza H Maxwell C et al Cognitive impairment individuals syphilis Abstract 1014 tDf HIV preexposure prophylaxis Abstract 104LB 54 Grulich Ae Guy r Amin J et al populationlevel effectiveness rapid targeted highcoverage rollout HIV preexposure prophylaxis men sex men epICnSW prospective cohort study Lancet HIV 2018 5 e629e637 55 Molina JM prep failures diagnosis resistance treatment Abstract 160 56 Marcus JL Hurley LB nguyen Dp et al redefining human immunodeficiency virus HIV preexposure prophylaxis failures Clin Infect Dis 2017 65 17681769 57 Souza MS pinyakorn S Akapirat S et al Initiation antiretroviral therapy acute HIV1 Infection leads high rate nonreactive HIV serology Clin Infect Dis 2016 63 555561 58 Hayes rJ Donnell DJ floyd S et al Impact universal testing treatment 43 Lake Je Wu K erlandson KM et al risk factors excess weight gain following Zambia South Africa Hptn071 popArt Abstract 92 switch integrase inhibitorbased Art Abstract 669 44 Bourgi K Jenkins C rebeiro pf et al Greater weight gain treatmentnaive persons starting integrase inhibitors Abstract 670 45 McComsey GA eron JJ Santiago S et al Weight gain treatment 3468 treatmentexperienced adults HIV Abstract 671 46 Kerchberger AM Sheth An Angert CD et al Integrase strand transfer inhibitors associated weight gain women Abstract 672 59 rockstroh JK Dynamics acute HCV Western europe Abstract 112 60 Garvey LJ Smith CJ Stingone C et al fall HCV incidence HIV MSM London following wider access DAA therapy Abstract 85 61 Martin nK thornton A Hickman M et al Can hepatitis C Virus HCV directacting antiviral treatment prevention reverse HCV epidemic men sex men United Kingdom epidemiological modeling insights Clin Infect Dis 2016 62 10721080 47 Landovitz rJ Zangeneh SZ Chau G et al CopD risk myocardial 62 Butt AA Aslam S Yan p et al Incident diabetes glucose control HCV infarction type people living HIV Abstract 31 treatment DAAs erCHIVeS Abstract 88 48 Bares SH Smeaton LM Vu V et al impact weight gain sex immune 63 torgersen J Kallan MJ Carbonari DM et al HIV viremia low CD4 increase activation following initiation Art Abstract 673 HCC risk advanced liver fibrosis Abstract 90 49 Crothers K Harding Bn Whitney BM et al Cabotegravir associated 64 Chappell CA Krans ee Bunge K et al A phase 1 study ledipasvirsofosbuvir weight gain HIVnegative individuals Hptn 077 Abstract 34LB pregnant women hepatitis C virus Abstract 87 50 freiberg M Duncan MS Kundu S et al Sudden cardiac death HIVinfected 65 Chappell CA Hillier SL Crowe D et al Hepatitis C virus screening children uninfected veterans Abstract 33 51 Battalora L Armon C palella fJ et al Breaking bones bad incident fracture mortality HIV outpatient study Abstract 30 52 Hillier SL Update HIV prevention Abstract 2003 exposed pregnancy Pediatrics 2018 141 66 Suryaprasad AG White JZ Xu f et al emerging epidemic hepatitis C virus infections young nonurban persons inject drugs United States 20062012 Clin Infect Dis 2014 59 14111419 Highlights CroI 2019 131